William Blair Investment Management LLC Takes Position in Halozyme Therapeutics, Inc. $HALO

William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,842,956 shares of the biopharmaceutical company’s stock, valued at approximately $124,031,000.

Other hedge funds have also modified their holdings of the company. Moran Wealth Management LLC grew its holdings in Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 151 shares during the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares during the last quarter. Alps Advisors Inc. lifted its position in Halozyme Therapeutics by 3.0% during the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 170 shares during the period. Pzena Investment Management LLC lifted its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 171 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 0.3%

NASDAQ:HALO opened at $68.32 on Friday. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The business’s 50 day moving average is $65.74 and its two-hundred day moving average is $68.75. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The company has a market cap of $8.10 billion, a PE ratio of 24.58, a P/E/G ratio of 0.28 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter last year, the business posted $1.11 EPS. Halozyme Therapeutics’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley reduced their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.67.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at approximately $974,014.80. This represents a 58.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,482 shares of company stock valued at $8,200,842 in the last quarter. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.